Related Experiment Video
Updated: Jun 17, 2026
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
Modeling type 2 diabetes in rats by administering tacrolimus
J C Quintana-Pérez1, F García-Dolores2, A S Valdez-Guerrero1
1Laboratorio de Investigación en Bioquímica Aplicada, Sección de Estudios de Posgrado e Investigación y Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Casco de Santo Tomas,Miguel Hidalgo, Ciudad de México, México.
A new study introduces a low-cost, non-obese rat model for type 2 diabetes using tacrolimus. This model mimics human disease markers, aiding in the development of new diabetes treatments and safer immunosuppressants.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Animal Models
Background:
- Type 2 diabetes prevalence is rising globally, with ~422 million cases currently.
- Existing animal models for type 2 diabetes have limitations, necessitating a better model.
- Current treatments cannot cure type 2 diabetes or halt its progression.
Purpose of the Study:
- To evaluate a novel, low-cost, non-obese type 2 diabetes model in Wistar rats.
- To assess the efficacy of tacrolimus in inducing type 2 diabetes-like pathology.
- To establish a model for testing new type 2 diabetes therapies and immunosuppressants.
Main Methods:
- Administered a high daily dose of tacrolimus to Wistar rats for 4 weeks.
- Monitored biochemical and antioxidant markers before and after treatment.
- Assessed fasting blood glucose, glucose tolerance, insulin tolerance, cholesterol, and triglyceride levels.
Main Results:
- Tacrolimus treatment induced hyperglycemia, hypoinsulinemia, and elevated cholesterol/triglycerides.
- Biochemical markers mimicked those observed in human type 2 diabetes.
- Pancreatic β-cell function and morphology were altered, correlating with observed pathology.
Conclusions:
- The tacrolimus-induced Wistar rat model effectively replicates key features of human type 2 diabetes.
- This model is suitable for evaluating novel type 2 diabetes treatments.
- The model can aid in designing immunosuppressants that avoid pancreatic damage and diabetes.
